NewsBenzingaRBC Capital mantiene il rating Outperform su Aptiv, abbassa il prezzo obiettivo a 64 dollari RBC Capital mantiene il rating Outperform su Aptiv, abbassa il prezzo obiettivo a 64 dollari Benzinga 2026.11.04 16:20 (GMT+0) Open on Benzinga Other news Piper Sandler Maintains Neutral on RxSight, Lowers Price Target to $8 RBC Capital Reiterates Outperform on Shopify, Maintains $200 Price Target Piper Sandler Maintains Underweight on Innovative Ind Props, Raises Price Target to $46 Piper Sandler Maintains Neutral on Atlas Energy Solutions, Lowers Price Target to $13 RBC Capital Maintains Sector Perform on Safehold, Lowers Price Target to $12 Zimmer Biomet Lifts Annual Growth Despite Challenging Knee Market
